TY - JOUR
T1 - The burden of idiopathic pulmonary fibrosis
T2 - An unmet public health need
AU - Lee, Augustine S.
AU - Mira-Avendano, Isabella
AU - Ryu, Jay H.
AU - Daniels, Craig E.
N1 - Funding Information:
Editorial assistance was provided by Joe Hirsch of BioScience Communications, New York, NY, and was funded by InterMune ® , Brisbane, CA.
PY - 2014/7
Y1 - 2014/7
N2 - Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal 3-year median survival, despite two decades of clinical trials. Increasingly recognized are the serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung cancer, and depression that further contribute to the substantial rise in the use of IPF-related healthcare resources. At present, lung transplantation remains the sole viable treatment for the few who qualify. Pharmacologic interventions targeting lung function and survival have remained largely disappointing, and very few investigations have specifically targeted comorbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope to highlight some of the unmet medical needs associated with IPF, and encourage both public support and further investigations into these and other patient-centered outcomes and not just that of survival and lung function.
AB - Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal 3-year median survival, despite two decades of clinical trials. Increasingly recognized are the serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung cancer, and depression that further contribute to the substantial rise in the use of IPF-related healthcare resources. At present, lung transplantation remains the sole viable treatment for the few who qualify. Pharmacologic interventions targeting lung function and survival have remained largely disappointing, and very few investigations have specifically targeted comorbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope to highlight some of the unmet medical needs associated with IPF, and encourage both public support and further investigations into these and other patient-centered outcomes and not just that of survival and lung function.
KW - Burden of illness
KW - Comorbid illness
KW - Epidemiology
KW - Health-related quality of life
KW - Healthcare utilization
KW - Idiopathic pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=84902375258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902375258&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2014.03.015
DO - 10.1016/j.rmed.2014.03.015
M3 - Review article
C2 - 24780718
AN - SCOPUS:84902375258
SN - 0954-6111
VL - 108
SP - 955
EP - 967
JO - Respiratory Medicine
JF - Respiratory Medicine
IS - 7
ER -